Zhengfang YI,Shihong PENG,Yundong HE,Wenbo Zhou,Yihua Chen,Mingyao Liu
申请号：
US15346743
公开号：
US20180125814A1
申请日:
2016.11.09
申请国别(地区):
US
年份:
2018
代理人:
摘要：
A pharmaceutical composition comprising an ailanthone (AIL) compound or a derivative thereof, for the treatment of diseases or conditions caused by, dependent from, or associated with excessive androgen receptor activity. Ailantone compounds have been discovered to be a potent inhibitor of both full-length AR (AR-FL) and constitutively-active truncated AR splice variants (AR-Vs), and are found to possess favorable drug-like properties such as good bioavailability, high solubility, lack of CYP inhibition, and low hepatotoxicity. Methods of treatment are also provided.
